794 



INDEX 



Serological classification of Pneumo- 

 coccus 

 acid agglutination, 109, 110 

 agglutination, 26, 103-118, 359-560, 



861-362 

 agglutinin-absorption, 110, 111, 362 

 atypical and typical strains, 105, 



116-117 

 Collin's observations, 104-105 

 complement fixation, 110 

 Cooper's classification, 113-115 

 cross-agglutination, 112 

 Dochez and Gillespie's groups, 106 

 electrophoretic potential, 118-119 

 fibrinous and cellular types, 105 

 Gordon's sub-groups, 111 

 Griffith's sub-groups, 112 

 Lister's groups, 107-108 

 Olmstead's groups, 108-109 

 Pneumococcus mucosvs, 105, 110, 



361-362, 380 

 protection tests, 104, 105, 106, 108, 



111, 113, 114 

 Streptococcus mucosus, 110, 361-362 

 Type II, sub-groups, 108, 110 

 Type determination, 119-132 

 unidentified strains in, 116-117 

 unsolved problems, 614 

 Serological reactions, technique, 641- 

 648 

 agglutination, 641 

 bactericidal tests, 647-648 

 complement fixation, 647 

 precipitation tests, 642-647 

 combining equivalents, 645-647 

 modified routine, 644-645 

 nitrogen determination, 643-644 

 optimal proportions, 642-643 

 protection tests, 648-661 

 Serological types of Pneumococcus. 

 See Pneumococcus ; Serological 

 classification 

 Serum 



antipneumococcic. See Antipneumo- 



coccic serum, production 

 anti-R. See Anti-R serum 

 as accessory substance in promot- 

 ing growth, 42 



Serum (cont.): 

 avian. See Avian serum 

 convalescent, 442 

 effect on acid production, 71 

 immune. See Immune serum 

 normal, effect on hemolysis, 84 

 normal, effect on phagocytosis, 392- 



393, 395-397 

 polyvalent, 545-547 

 protective action of normal human, 



434 

 sterility tests, 662-663 

 swine. See Swine serum 

 Serum-glucose agar as differential 



medium, 47 

 Serum-leucocyte mixtures, pneumo- 

 coccidal action of, 429, 430, 435, 

 439 

 Serum treatment of lobar pneumonia, 

 598-612 

 antagonistic substances, 601 

 duration of acute symptoms, 604 

 effect on temperature, 605 

 fatality rate, Types I and II, 607 

 influence of bacteriemia, 609, 610, 



611 

 limitations, 599-602 

 rationale, 598-599 

 results, 602-612 

 skin reactions as guide, 468 

 Shwartzman phenomenon, 474-476 

 Sinusitis, Pneumococcus in, 226, 227 

 Skin allergy, active and passive, 466- 

 468 

 See also Skin reactions 

 Skin reactions, 455-460, 471 



as guide to serum treatment, 468 

 delayed reactions, 464, 465, 468 

 immediate reactions, 464, 473 

 in horses immunized, actively and 



passively, 458 

 in pneumonia, 440, 460-466, 468, 473 

 in rabbits immunized, actively and 



passively, 458 

 mechanism, 468-474 

 recurrence, 460 



Shwartzman phenomenon, 474-476 

 to autolysates, 456, 461, 462, 466 



